Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.

Source :: The Medical letter on drugs and therapeutics [Med Lett Drugs Ther] 2016 Mar 28; Vol. 58 (1491), pp. 41-2.
Publication Year :: 2016

Subjects :: Administration, Oral
Aminophenols administration & dosage
Aminophenols adverse effects
Aminophenols economics
Aminophenols pharmacokinetics
Aminopyridines administration & dosage
Aminopyridines adverse effects
Aminopyridines economics
Aminopyridines pharmacokinetics
Benzodioxoles administration & dosage
Benzodioxoles adverse effects
Benzodioxoles economics
Benzodioxoles pharmacokinetics
Cystic Fibrosis diagnosis
Cystic Fibrosis economics
Cystic Fibrosis genetics
Cystic Fibrosis Transmembrane Conductance Regulator drug effects
Cystic Fibrosis Transmembrane Conductance Regulator genetics
Drug Combinations
Drug Costs
Drug Interactions
Humans
Membrane Transport Modulators administration & dosage
Membrane Transport Modulators adverse effects
Membrane Transport Modulators economics
Membrane Transport Modulators pharmacokinetics
Mutation
Quinolones administration & dosage
Quinolones adverse effects
Quinolones economics
Quinolones pharmacokinetics
Risk Factors
Treatment Outcome
Aminophenols therapeutic use
Aminopyridines therapeutic use
Benzodioxoles therapeutic use
Cystic Fibrosis drug therapy
Membrane Transport Modulators therapeutic use
Quinolones therapeutic use

Tools